Physician profile
Anne Hatch
NPI 1457766792
$13,702.98
in general payments reported to CMS, 2019-2025
20 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $930 · 2020: $2,087 · 2021: $1,437 · 2022: $7,320 · 2023: $1,067 · 2024: $470 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.24 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $9,535.19 | 2019-2025 | Soliris, Ultomiris |
| Ipsen Pharma Sas | $1,228.90 | 2022 | |
| Grifols USA, LLC | $815.45 | 2019-2023 | Gamunex-C |
| Abbvie INC. | $374.54 | 2022-2024 | |
| Argenx US, INC. | $334.31 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Ucb, INC. | $255.42 | 2023 | |
| Janssen Biotech, INC. | $214.38 | 2025 | |
| Tanabe Pharma America, INC. | $203.94 | 2019-2024 | |
| Grifols Shared Services North America, INC. | $129.28 | 2024 | Gamunex-C |
| Emd Serono, INC. | $125.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $119.81 | 2022 | |
| Biogen, INC. | $109.29 | 2021-2022 | |
| Edw Pharma, INC. | $73.41 | 2021 | |
| Acadia Pharmaceuticals INC | $64.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.40 | 2025 | Hyqvia |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedrion Biopharma, INC. | $40.17 | 2024 | Koate, Kedrab, Gammaked |
| Acorda Therapeutics, INC | $20.00 | 2019 | |
| Akcea Therapeutics, INC. | $12.46 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Hatch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.